ICH E2D(R1) brings renewed attention to how organizations identify, assess and oversee safety information generated outside traditional pharmacovigilance channels. Explore key governance considerations and how to assess whether your current framework is ready.
Clinical Quality is moving upstream. Explore key insights from senior Quality leaders on proactive risk management, vendor oversight, data-enabled QA and the evolving role of Quality as a strategic partner.
Understanding the transformative impact of ICH E6(R3) guidelines on clinical trial oversight and quality management.
In this free guide, we break down the most critical updates to ICH E6(R3)—and provide practical, inspection-ready strategies to help you stay compliant, audit-ready, and ahead of regulatory expectations.
ADAMAS Consulting’s proven Risk-Based Quality Assurance (RBQA) process—designed to help sponsors meet the evolving requirements of ICH E6 (R3) with confidence
Discover how ADAMAS helped a sponsor prepare for inspection using a targeted risk-based approach
ADAMAS Consulting’s webinar, “GCP ICH E6 R3 Unveiled: Navigating the Evolving Roles of Sponsors and CROs,” provides invaluable insights into the evolving landscape of Good Clinical Practice (GCP) guidelines. Experts discuss key updates to ICH E6 R3 and how Sponsors...
Understand key Windsor Framework changes for UK pharmacovigilance in 2025 and how MAHs can stay compliant under new MHRA rules
From Reactive Compliance to Strategic Partnership: How Clinical Quality Is Evolving
RQA 8th Global QA Conference 2026 | London, UK
FDA’s Real-Time Clinical Trial Initiative: Endorses Data-Enabled QA Oversight
SCOPE Europe 2026 | Barcelona, Spain
Beyond Audit Cycles: A Risk-Based Approach to Regulatory Excellence in Pharmacovigilance